Alnylam Pharmaceuticals, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?

Alnylam vs. Veracyte: SG&A Cost Management Showdown

__timestampAlnylam Pharmaceuticals, Inc.Veracyte, Inc.
Wednesday, January 1, 20144452600040786000
Thursday, January 1, 20156061000047876000
Friday, January 1, 20168935400052035000
Sunday, January 1, 201719936500055348000
Monday, January 1, 201838235900065276000
Tuesday, January 1, 201947900500082720000
Wednesday, January 1, 202058842000089118000
Friday, January 1, 2021620639000181193000
Saturday, January 1, 2022770658000174078000
Sunday, January 1, 2023795646000184232000
Monday, January 1, 2024975526000
Loading chart...

Infusing magic into the data realm

Who Manages SG&A Costs Better: Alnylam Pharmaceuticals or Veracyte?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Alnylam Pharmaceuticals and Veracyte, Inc. have shown contrasting trends in their SG&A expenses over the past decade. From 2014 to 2023, Alnylam's SG&A costs surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Veracyte's expenses grew by approximately 350%, indicating a more conservative approach.

Alnylam's expenses peaked in 2023, reaching nearly four times that of Veracyte's. This disparity highlights Alnylam's strategy of prioritizing growth, while Veracyte focuses on cost efficiency. As investors and stakeholders evaluate these companies, understanding their financial strategies provides insight into their long-term sustainability and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025